|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12345678910111213...1819» |
- || Humira (adalimumab) / AbbVie
Trial primary completion date: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Apr 19, 2015
P4, N=100, Recruiting, Sponsor: Innovaderm Research Inc.
Trial primary completion date: Nov 2014 --> Nov 2015
- Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=200, Recruiting, Sponsor: University of California, Davis
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jan 2015 --> Jan 2025
- || Trial primary completion date: EPIDEPSO: Clinical Assessment and Psychosocial Impact of Psoriasis (clinicaltrials.gov) - Apr 15, 2015
P4, N=719, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Trial primary completion date: Jan 2015 --> Jan 2025 Trial primary completion date: Jan 2015 --> Nov 2015
- ||| Trial completion, Enrollment change, Trial primary completion date: Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=409, Completed, Sponsor: Northwestern University
Trial primary completion date: Jan 2015 --> Nov 2015 Recruiting --> Completed | N=576 --> 409 | Trial primary completion date: Jun 2015 --> Jun 2012
- Bimzelx (bimekizumab) / UCB
Clinical: Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Apr 14, 2015
P1, N=50, Recruiting, Sponsor: UCB Celltech
Recruiting --> Completed | N=576 --> 409 | Trial primary completion date: Jun 2015 --> Jun 2012 Trial primary completion date: May 2015 --> Aug 2015
- ||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis (clinicaltrials.gov) - Apr 10, 2015
P3, N=51, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Trial primary completion date: May 2015 --> Aug 2015 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=198, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Trial completion, Enrollment change, Trial primary completion date: National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study (clinicaltrials.gov) - Apr 8, 2015
P4, N=22, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Dec 2014 --> Jun 2014
- ||||| pefcalcitol (M 518101) / Maruho
Enrollment closed, Trial primary completion date: Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Mar 31, 2015
P3, N=522, Active, not recruiting, Sponsor: Maruho North America Inc.
Recruiting --> Completed | N=44 --> 22 | Trial primary completion date: Dec 2014 --> Jun 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015
- ||||| pefcalcitol (M 518101) / Maruho
Enrollment closed, Trial primary completion date: Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis (clinicaltrials.gov) - Mar 31, 2015
P3, N=522, Active, not recruiting, Sponsor: Maruho North America Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015
- Trial completion, Trial primary completion date: IL-17 Role in Variants of Psoriasis (clinicaltrials.gov) - Mar 27, 2015
P=N/A, N=90, Completed, Sponsor: Innovaderm Research Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Feb 2015
- |||| VB-201 / VBL Therap
Trial completion: A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis (clinicaltrials.gov) - Mar 27, 2015
P2, N=194, Completed, Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Feb 2015 Active, not recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
Enrollment change: STATURE: Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (clinicaltrials.gov) - Mar 18, 2015
P3, N=43, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=140 --> 43
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: FUTURE 3: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis (clinicaltrials.gov) - Mar 17, 2015
P3, N=414, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=140 --> 43 Recruiting --> Active, not recruiting
- |||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, Trial primary completion date: Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP) (clinicaltrials.gov) - Mar 9, 2015
P4, N=1852, Completed, Sponsor: Kristian Reich, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014
- ||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Trial initiation date, Trial primary completion date, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 7, 2015
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014 Initiation date: Sep 2013 --> Jun 2015 | Trial primary completion date: Aug 2014 --> Jun 2017
- | Xeljanz (tofacitinib) / Pfizer, PF-06263276 / Pfizer
Clinical: A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (clinicaltrials.gov) - Mar 7, 2015
P1, N=15, Completed, Sponsor: Pfizer
Initiation date: Sep 2013 --> Jun 2015 | Trial primary completion date: Aug 2014 --> Jun 2017 Recruiting --> Completed | N=20 --> 15
- Enbrel (etanercept) / Pfizer, Amgen
Trial termination: Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus (clinicaltrials.gov) - Mar 3, 2015
P2, N=27, Terminated, Sponsor: Stanford University
Recruiting --> Completed | N=20 --> 15 Completed --> Terminated; Slow recruitment
- | Prurisol (abacavir gylcolate) / Innovation Pharma
Trial completion: Bioequivalence and Pharmacokinetic Study of Prurisol (clinicaltrials.gov) - Mar 3, 2015
P1, N=18, Completed, Sponsor: Cellceutix Corporation
Completed --> Terminated; Slow recruitment Active, not recruiting --> Completed
- Biomarker, Trial completion: Evaluate the Effect of Elimune Capsules (clinicaltrials.gov) - Mar 2, 2015
P1, N=20, Completed, Sponsor: Elorac, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- |||| remtolumab (ABT-122) / AbbVie
Enrollment open, P2 data: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Feb 27, 2015
P2, N=220, Recruiting, Sponsor: AbbVie
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: GESTURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (clinicaltrials.gov) - Feb 26, 2015
P3, N=205, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Nov 2016
- |||||| Cosentyx (secukinumab) / Novartis
Enrollment open: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (clinicaltrials.gov) - Feb 26, 2015
P3, N=1144, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2015 --> Nov 2016 Active, not recruiting --> Recruiting
- ||||| Hyrimoz (adalimumab-adaz) / Sandoz
Enrollment closed: ADACCESS: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (clinicaltrials.gov) - Feb 23, 2015
P3, N=448, Active, not recruiting, Sponsor: Sandoz
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Observational data, Trial primary completion date: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jan 2015 --> Apr 2015
- Trial initiation date, Trial primary completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - Feb 20, 2015
P2, N=10, Not yet recruiting, Sponsor: Tissa Hata, MD
Trial primary completion date: Jan 2015 --> Apr 2015 Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2016
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Feb 20, 2015
P4, N=64, Active, not recruiting, Sponsor: Amgen
Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Aug 2015 --> Jul 2016 Recruiting --> Active, not recruiting | N=100 --> 64 | Trial primary completion date: Nov 2016 --> May 2015
- Enrollment open: The NOR-SWITCH Study (clinicaltrials.gov) - Feb 19, 2015
P4, N=500, Recruiting, Sponsor: Diakonhjemmet Hospital
Recruiting --> Active, not recruiting | N=100 --> 64 | Trial primary completion date: Nov 2016 --> May 2015 Not yet recruiting --> Recruiting
- || Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial completion, Trial primary completion date: An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis (clinicaltrials.gov) - Feb 19, 2015
P3, N=30, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014
- ||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial completion, Trial primary completion date: A Phase 3 Clinical Study of KHK4827 (clinicaltrials.gov) - Feb 19, 2015
P3, N=145, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Feb 2015
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial primary completion date, Monotherapy: Acitretin and Etanercept in Psoriasis (clinicaltrials.gov) - Feb 19, 2015
P2, N=10, Completed, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Feb 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2009 --> Mar 2009
- |||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis (clinicaltrials.gov) - Feb 12, 2015
P4, N=118, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: Jun 2009 --> Mar 2009 Not yet recruiting --> Recruiting
- | neihulizumab (ALTB-168) / AltruBio
Enrollment open: A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) - Feb 10, 2015
P2, N=15, Recruiting, Sponsor: AbGenomics B.V Taiwan Branch
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Tremfya (guselkumab) / J&J
Trial completion: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 9, 2015
P2, N=293, Completed, Sponsor: Janssen Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Phase classification: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=8, Terminated, Sponsor: Wayne State University
Active, not recruiting --> Completed Phase classification: P2 --> P1/2
- |||| toreforant (JNJ-38518168) / J&J
Enrollment open: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Feb 3, 2015
P2, N=66, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P1/2 Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Feb 2, 2015
P1, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Not yet recruiting --> Recruiting Phase classification: P1b --> P1
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial completion: Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects (clinicaltrials.gov) - Jan 30, 2015
P1, N=30, Completed, Sponsor: Amgen
Phase classification: P1b --> P1 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial primary completion date: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=203, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=266 --> 203 | Trial primary completion date: Sep 2015 --> Mar 2016
- | Januvia (sitagliptin) / Merck (MSD)
New P2 trial: Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (clinicaltrials.gov) - Jan 28, 2015
P2, N=120, Recruiting, Sponsor: University College Dublin
- ||||| remtolumab (ABT-122) / AbbVie
New P2 trial, P2 data: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Jan 28, 2015
P2, N=220, Not yet recruiting, Sponsor: AbbVie
- | rose bengal disodium (PH-10) / Provectus
Enrollment open: A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 (clinicaltrials.gov) - Jan 26, 2015
P2, N=30, Recruiting, Sponsor: Provectus Pharmaceuticals
N=266 --> 203 | Trial primary completion date: Sep 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- Enrollment change: EPIDEPSO: Clinical Assessment and Psychosocial Impact of Psoriasis (clinicaltrials.gov) - Jan 22, 2015
P4, N=3, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Not yet recruiting --> Recruiting N=800 --> 3
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: DERM: An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=50, Enrolling by invitation, Sponsor: Universitaire Ziekenhuizen Leuven
N=800 --> 3 Not yet recruiting --> Enrolling by invitation
- |||| bleselumab (ASKP1240) / Astellas, Kyowa Kirin
Trial completion: A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 22, 2015
P2, N=60, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- | Cosentyx (secukinumab) / Novartis
Biomarker, Trial completion: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients (clinicaltrials.gov) - Jan 20, 2015
P2, N=36, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current (clinicaltrials.gov) - Jan 15, 2015
P2/3, N=36, Completed, Sponsor: Pr PASSERON
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Sep 2013
- trichuris suis ova (CNDO-201) / Fortress
Trial completion: Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 15, 2015
P1, N=8, Completed, Sponsor: Mark Lebwohl
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Sep 2013 Active, not recruiting --> Completed
- ||||||| pefcalcitol (M 518101) / Maruho
Trial completion: Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients (clinicaltrials.gov) - Jan 6, 2015
P3, N=788, Completed, Sponsor: Maruho Europe Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed